22nd Century Group, Inc. (XXII)
Company Info
US90137F1030
90137F103
Jan 26, 2011
Highlights
$5.13M
$50.65
0.02
$21.69M
-$1.88M
-$10.58M
$0.70 - $147.15
$720.00
15.21%
0.41
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
Loading data...
Returns By Period
22nd Century Group, Inc. (XXII) returned -85.41% year-to-date (YTD) and -99.53% over the past 12 months. Over the past 10 years, XXII returned -54.78% annually, underperforming the S&P 500 benchmark at 10.84%.
XXII
-85.41%
-4.23%
-94.46%
-99.53%
-94.11%
-78.48%
-54.78%
^GSPC (Benchmark)
0.52%
6.32%
-1.44%
12.25%
12.45%
14.20%
10.84%
Monthly Returns
The table below presents the monthly returns of XXII, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | -22.60% | -53.28% | -25.00% | -40.97% | -8.85% | -85.41% | |||||||
| 2024 | -5.59% | -20.42% | -14.22% | 1,216.67% | -44.26% | -15.32% | -9.71% | -52.61% | -32.59% | -51.84% | -4.05% | -60.43% | -78.88% |
| 2023 | 19.50% | -17.86% | -14.89% | -7.62% | -12.60% | -38.36% | -39.38% | -59.48% | -30.65% | -54.08% | -42.09% | -28.38% | -98.65% |
| 2022 | -29.77% | 7.83% | -0.85% | -17.67% | -4.71% | 17.03% | -21.13% | -20.24% | -30.80% | 41.27% | -9.92% | -21.99% | -70.21% |
| 2021 | 13.64% | 34.00% | -1.79% | 42.25% | -3.85% | 2.89% | -30.67% | 11.21% | -17.09% | -7.43% | -8.39% | 23.11% | 40.45% |
| 2020 | -15.75% | -20.16% | 1.35% | 25.36% | -11.90% | -7.71% | 3.65% | -25.55% | 8.63% | 13.44% | 118.74% | 38.36% | 100.00% |
| 2019 | -10.04% | 7.59% | -29.05% | 28.07% | -12.79% | 9.42% | -23.92% | 23.27% | 15.31% | -16.37% | -45.50% | 6.80% | -55.82% |
| 2018 | 21.79% | -26.39% | -6.37% | -11.91% | 2.42% | 16.04% | 1.63% | 8.40% | 3.69% | -13.88% | 25.62% | -18.09% | -11.07% |
| 2017 | -12.84% | 1.05% | 22.92% | 18.64% | -2.14% | 27.74% | -0.00% | 25.71% | 25.91% | -23.47% | 9.91% | 20.17% | 156.88% |
| 2016 | -10.71% | -23.20% | -18.44% | 4.21% | 12.02% | -11.16% | 4.58% | 20.10% | 42.16% | -11.03% | -24.03% | 11.22% | -22.14% |
| 2015 | -29.09% | -30.16% | 5.25% | 17.44% | 5.94% | -12.15% | -19.15% | 2.07% | 8.29% | 67.86% | 5.67% | -6.04% | -15.15% |
| 2014 | 21.03% | 67.57% | -25.12% | -17.54% | 13.81% | 0.66% | -22.15% | 27.61% | -17.38% | -12.70% | -10.91% | -15.82% | -22.90% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of XXII is 7, meaning it’s performing worse than 93% of other stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for 22nd Century Group, Inc. (XXII) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Loading data...
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading data...
Worst Drawdowns
The table below displays the maximum drawdowns of the 22nd Century Group, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the 22nd Century Group, Inc. was 99.99%, occurring on Apr 21, 2025. The portfolio has not yet recovered.
The current 22nd Century Group, Inc. drawdown is 99.99%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -99.99% | Mar 11, 2014 | 2796 | Apr 21, 2025 | — | — | — |
| -85.82% | Mar 11, 2011 | 284 | Oct 2, 2012 | 187 | Jul 30, 2013 | 471 |
| -42.51% | Aug 2, 2013 | 71 | Nov 11, 2013 | 27 | Dec 19, 2013 | 98 |
| -15.89% | Jan 2, 2014 | 6 | Jan 9, 2014 | 1 | Jan 10, 2014 | 7 |
| -12.13% | Jan 13, 2014 | 8 | Jan 23, 2014 | 5 | Jan 30, 2014 | 13 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading data...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of 22nd Century Group, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Earnings Per Share
The chart presents the Earnings Per Share (EPS) performance of 22nd Century Group, Inc., comparing actual results with analytics estimates. The company has exceeded analyst expectations for EPS in the past quarter, achieving a 95.8% positive surprise.
Valuation
The Valuation section provides an overview of how 22nd Century Group, Inc. is priced in the market compared to other companies in the Drug Manufacturers - Specialty & Generic industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for XXII, comparing it with other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, XXII has a P/E ratio of 0.0. This P/E ratio is considered low compared to industry peers, which may suggest that the stock is undervalued or that the company has weaker growth prospects.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for XXII compared to other companies in the Drug Manufacturers - Specialty & Generic industry. XXII currently has a PEG ratio of 0.0. This PEG ratio is low compared to industry peers, which could indicate the stock is undervalued relative to its expected growth.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for XXII relative to other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, XXII has a P/S ratio of 0.2. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for XXII in comparison with other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, XXII has a P/B value of 1.4. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |